Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
Matsushita T, Suzuki N, Nagao A, Nagae C, Yamaguchi-Suita H, Kyogoku Y, Ioka A, Nogami K. Matsushita T, et al. Among authors: nogami k. BMJ Open. 2022 Mar 14;12(3):e057018. doi: 10.1136/bmjopen-2021-057018. BMJ Open. 2022. PMID: 35288393 Free PMC article. Clinical Trial.
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF; A-LONG Investigators. Mahlangu J, et al. Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13. Blood. 2014. PMID: 24227821 Free PMC article. Clinical Trial.
The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors.
Yoshioka A, Ishii E, Ueno T, Usami I, Kobayashi M, Kobayashi R, Sotomatsu M, Shirahata A, Suzuki T, Taki M, Ishida Y, Matsushita T, Shima M, Nogami K, Sakai M, Kigasawa H, Fukutake K. Yoshioka A, et al. Among authors: nogami k. Int J Hematol. 2015 Apr;101(4):362-8. doi: 10.1007/s12185-015-1734-z. Epub 2015 Feb 18. Int J Hematol. 2015. PMID: 25690486
Bispecific antibody mimicking factor VIII.
Nogami K. Nogami K. Thromb Res. 2016 May;141 Suppl 2:S34-5. doi: 10.1016/S0049-3848(16)30361-9. Thromb Res. 2016. PMID: 27207420 Review.
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Shima M, et al. Among authors: nogami k. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769. N Engl J Med. 2016. PMID: 27223146 Free article. Clinical Trial.
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. Shinkoda Y, et al. Among authors: nogami k. Haemophilia. 2017 Jan;23(1):59-66. doi: 10.1111/hae.13050. Epub 2016 Aug 1. Haemophilia. 2017. PMID: 27480904 Clinical Trial.
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Int J Hematol. 2017 Nov;106(5):704-710. doi: 10.1007/s12185-017-2265-6. Epub 2017 May 26. Int J Hematol. 2017. PMID: 28550352 Clinical Trial.
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Int J Hematol. 2018 Jan;107(1):123-124. doi: 10.1007/s12185-017-2369-z. Int J Hematol. 2018. PMID: 29149425
419 results